Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Hain Celestial Q2 Profit Rises, Sees Full Year Revenue Below View, Stock Falls

RELATED NEWS
Trade HAIN now with 

Natural and organic products company Hain Celestial Group Inc. (HAIN: Quote) Tuesday said profit in the second quarter increased significantly from last year, backed by a nearly 25 percent increase in revenues. Looking ahead, the company forecast full year revenues below Wall Street estimates. The stock fell almost 5 percent in the extended trade.

Net income climbed to $31.62 million or $0.67 per share from $20.04 million or $0.44 per share reported last year.

Adjusted earnings from continuing operations were $0.72 per share, while it stood at $0.53 per share last year. On average, 14 analysts polled by Thomson Reuters expected the company to earn $0.69 per share for the quarter. Analysts' estimates typically exclude special items.

The latest adjusted results exclude acquisition-related expenses, integration and restructuring charges as well as an acquisition-related currency gain.

Net sales increased to $455.32 million from $364.84 million. Analysts estimated revenues of $473.44 million for the quarter.

Hain Celestial US generated $280.4 million in the quarter and in the U.K., Hain Daniels' net sales were $120.2 million. For the Rest of World segment, which comprises operations of Hain Celestial Canada and Hain Celestial Europe, net sales were $54.7 million.

Looking forward to full year 2013, the company expects earnings of $2.40 to $2.47 per share, and net sales in the range of $1.740 billion to $1.755 billion. Analysts currently estimate earnings of $2.42 per share on revenues of $1.77 billion.

HAIN added 3.4 percent to close at $59.40 on Tuesday. The stock fell 4.6 percent in the extended trade.

Register
To receive FREE breaking news email alerts for The Hain Celestial Group, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.